ATX 1.61% 6.1¢ amplia therapeutics limited

Ann: Update on ACCENT Trial in Pancreatic Cancer, page-6

  1. 1,840 Posts.
    lightbulb Created with Sketch. 33
    Don’t forget they trialled 14 patients on 3 dose levels, so arguably the lower doses may not have moved the needle as much as the higher doses which is what 2a will look at - if the 3 continuers were on 400mg that that is extremely encouraging of itself.
 
watchlist Created with Sketch. Add ATX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.